belantamab mafodotin
belantamab mafodotin is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Blenrep. Available dosage forms: injection, powder, for solution, liquid.
Drug Details
- Generic Name
- belantamab mafodotin
- Brand Names
- Blenrep
- Application Number
- BLA761440
- Sponsor
- GlaxoSmithKline LLC
- NDC Codes
- 2
- Dosage Forms
- INJECTION, POWDER, FOR SOLUTION, LIQUID
- Routes
- INTRAVENOUS
- Active Ingredients
- BELANTAMAB MAFODOTIN
Indications and Usage
1 INDICATIONS AND USAGE BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP, a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate, is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. ( 1 )